Sapporo, Japan

Mineo Saneyoshi

This inventor holds 1 USPTO granted patent. Top assignee: Teijin Limited. Active years: 1990.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mineo Saneyoshi. Retrieved from https://idiyas.com/inventor/mineo-saneyoshi-6dca1pyh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1990

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Mineo Saneyoshi

Introduction

Mineo Saneyoshi is a notable inventor based in Sapporo, Japan. He has made significant contributions to the field of antitumor research. His work focuses on developing innovative compositions that can aid in cancer treatment.

Latest Patents

Mineo Saneyoshi holds a patent for an antitumor composition comprising a pyrimidine type nucleic acid derivative. This patent includes an antitumor agent that features at least one pyrimidine type nucleic acid derivative with a specific general formula. The composition also incorporates a 1-[(2-hydroxyethoxy)methyl]uracil derivative, which enhances its effectiveness. He has 1 patent to his name.

Career Highlights

Saneyoshi is currently associated with Teijin Limited, a company known for its advancements in various technological fields. His role at Teijin Limited allows him to further his research and development efforts in innovative medical solutions.

Collaborations

Throughout his career, Mineo Saneyoshi has collaborated with esteemed colleagues such as Masahiko Saito and Takeo Kawaguchi. These collaborations have contributed to the advancement of his research and the successful development of his patented compositions.

Conclusion

Mineo Saneyoshi's work exemplifies the impact of innovative research in the medical field. His contributions to antitumor compositions highlight the importance of continued exploration and development in cancer treatment.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…